Analysts expect ContraVir Pharmaceuticals Inc (NASDAQ:CTRV) to announce ($0.09) earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Zero analysts have provided estimates for ContraVir Pharmaceuticals’ earnings. ContraVir Pharmaceuticals posted earnings of ($0.16) per share in the same quarter last year, which suggests a positive year over year growth rate of 43.8%. The company is scheduled to report its next earnings report on Wednesday, September 27th.

On average, analysts expect that ContraVir Pharmaceuticals will report full year earnings of ($0.41) per share for the current year. For the next fiscal year, analysts anticipate that the company will report earnings of ($0.41) per share. Zacks’ earnings per share calculations are an average based on a survey of sell-side research firms that cover ContraVir Pharmaceuticals.

CTRV has been the topic of several analyst reports. Noble Financial reaffirmed a “buy” rating on shares of ContraVir Pharmaceuticals in a research report on Friday, April 21st. Maxim Group reaffirmed a “buy” rating and set a $4.00 price target on shares of ContraVir Pharmaceuticals in a research report on Tuesday, April 4th.

ContraVir Pharmaceuticals (NASDAQ:CTRV) opened at 0.711 on Monday. ContraVir Pharmaceuticals has a 1-year low of $0.62 and a 1-year high of $2.65. The stock’s 50 day moving average price is $1.27 and its 200-day moving average price is $1.56. The company’s market cap is $45.30 million.

A number of hedge funds have recently bought and sold shares of the stock. Teachers Advisors LLC increased its stake in ContraVir Pharmaceuticals by 3.1% in the fourth quarter. Teachers Advisors LLC now owns 298,781 shares of the biopharmaceutical company’s stock valued at $1,820,000 after buying an additional 8,862 shares during the period. Vanguard Group Inc. increased its stake in ContraVir Pharmaceuticals by 10.2% in the first quarter. Vanguard Group Inc. now owns 2,048,283 shares of the biopharmaceutical company’s stock valued at $3,626,000 after buying an additional 189,634 shares during the period. Geode Capital Management LLC increased its stake in ContraVir Pharmaceuticals by 2.0% in the first quarter. Geode Capital Management LLC now owns 353,777 shares of the biopharmaceutical company’s stock valued at $626,000 after buying an additional 7,057 shares during the period. Finally, Morgan Stanley increased its stake in ContraVir Pharmaceuticals by 0.4% in the first quarter. Morgan Stanley now owns 278,798 shares of the biopharmaceutical company’s stock valued at $493,000 after buying an additional 1,119 shares during the period. Hedge funds and other institutional investors own 5.49% of the company’s stock.

WARNING: This article was first published by American Banking News and is the property of of American Banking News. If you are accessing this article on another website, it was illegally copied and reposted in violation of U.S. and international trademark & copyright legislation. The correct version of this article can be viewed at https://www.americanbankingnews.com/2017/05/15/zacks-brokerages-expect-contravir-pharmaceuticals-inc-ctrv-will-announce-earnings-of-0-09-per-share.html.

About ContraVir Pharmaceuticals

ContraVir Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on the development of antiviral drugs for the treatment of Hepatitis B virus (HBV) infections. The Company develops a range of compounds to treat HBV infection, which include CMX157 and CRV431. The Company is also developing an antiviral asset, FV-100.

5 Day Chart for NASDAQ:CTRV

Get a free copy of the Zacks research report on ContraVir Pharmaceuticals (CTRV)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for ContraVir Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ContraVir Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.